Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro

International Journal of Antimicrobial Agents

Volumn 15, Issue 2, 2000, Pages 103-109

  Murakami, Junko ^a   Kishi, Kenji ^a   Hirai, Kazuhiro ^a   Hiramatsu, Kazufumi ^a   Yamasaki, Tohru ^a   Nasu, Masaru ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Clindamycin; Escherichia coli O157:H7; Macrolides; Shiga like toxins

Indexed keywords

CEFDINIR; CLINDAMYCIN; FOSFOMYCIN; LEVOFLOXACIN; MACROLIDE; ROKITAMYCIN; ROXITHROMYCIN; SHIGA TOXIN;

ANIMAL CELL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG RELEASE; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CEPHALOSPORINS; CERCOPITHECUS AETHIOPS; CLINDAMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI O157; FOSFOMYCIN; HUMANS; LATEX FIXATION TESTS; MICROBIAL SENSITIVITY TESTS; MIOCAMYCIN; OFLOXACIN; ROXITHROMYCIN; SHIGA-LIKE TOXIN I; SHIGA-LIKE TOXIN II; TIME FACTORS; VERO CELLS;

EID: 0034117183     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00126-6     Document Type: Article

References (21)

1. Riley L.W., Blake P.A., Cohen M.L., et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. New Engl. J. Med. 308:1983;681-685.
2. Rodrigue D.C., Barrett T.J., Griffin P.M., et al. A university outbreak of Escherichia coli O157:H7 infections associated with roast beef and an unusually benign clinical course. J. Infect. Dis. 172:1995;1122-1125.
3. Carter A.O., Korn D.A., Lior H., et al. A severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. New Engl. J. Med. 317:1987;1496-1500.
4. Ackers M.L., Griffin P.M., Slutsker L., et al. An outbreak of Escherichia coli O157:H7 infectious associated with leaf lettuce consumption. J. Infect. Dis. 177:1998;1588-1593.
5. Karmali M.A., Steele B.T., Petric M., Lim C. Sporadic cases of haemolytic-urermic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. I:1983;619-620.
6. Cleary T.G. Escherichia coli that cause hemolytic uremic syndrome. Infect. Dis. Clin. N. Am. 6:1992;163-176.
7. Hamano S., Yoshihiro O., Shunji A., et al. Neurological manifestations of hemorrhagic colitis in the outbreak of Escherichia coli O157:H7 infection in Japan. Acta Paediatr. 82:1993;454-458.
8. Tzipori S., Chow C.W., Powell H.R. Cerebral infection with Escherichia coli O157:H7 in humans and gnotobiotic piglets. J. Clin. Pathol. 41:1988;1099-1103.
9. Walterspiel J.N., Ashkenazi S., Morrow A.L., Cleary T.G. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin 1. Infection. 20:1992;25-29.
10. Yoh M., Honda T. The stimulating effect of fosfomycin, an antibiotic in common use in Japan, on the production/release of verotoxin-1 from enterohaemorrhagic Escherichia coli O157:H7 in vitro. Epidemiol. Infect. 119:1997;101-103.
11. Takahashi K., Yoshida T., Yokochi T., et al. Low-level release of Shiga-like toxin (Verocytotoxin) and endotoxin from enterohemorrhagic Escherichia coli treated with imipenem. Antimicrob. Agents Chemother. 41:(10):1997;2295-2296.
12. Mizukane R., Hirakata Y., Yamaguchi K., et al. Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 38:1994;528-533.
13. Stevens D.L., Bryant A.E., Hackett S.P. Antibiotic effects on bacterial viability, toxin production, and host response. Clin. Infect. Dis. 20:1995;154-157.
14. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, PA, 1993.
15. Pavia A.T., Nichols C.R., Blake P.A. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J. Pediatr. 116:1992;544-551.
16. Ostroff S.M., Kobayashi J.M., Lewis J.H. Infections with Escherichia coli O157:H7 in Washington state. J. Am. Med. Assoc. 262:1989;355-359.
17. Shibl A.M. Selective inhibition of enzyme synthesis by lincomycin in Staphylococcus aureus. J. Antimicrob. Chemother. 13:1984;625-627.
18. Lorian V., Gemmel C.G. Effect of low antibiotic concentrations on bacteria. Antibiotics in Laboratory Medicine. 1991;Williams and Wilkins, Baltimore, MD.
19. Karpman D., Connell H., Svensson M., Scheutz F., Alm P., Svanborg C. The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J. Infect. Dis. 175:1997;611-620.
20. Louise C.B., Obrig T.G. Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 β, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect. Immun. 59:1991;4173-4179.
21. Kishi K., Hirai K., Hiramatsu K., Yamasaki T., Nasu M. Clindamycin suppresses endotoxin released by ceftazidime-treated Escherichia coli O55:B5 and subsequent production of tumor necrosis factor alpha and interleukin 1β Antimicrob. Agents Chemother. 3:1999;616-622.